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Abstract 
In the last 100 years, intensive studies have been done on the identification of the systematic 
approaches to find the cure for the chronic heart failure, however the mystery remains unresolved 
due to its complicated pathogenesis and ineffective early diagnosis. The present investigation was 
aimed to evaluate the potential effects of the traditional chinese medicine, Xinmailong, on the 
chronic heart failure (CHF) patients as compared to the standard western medical treatment 
available so far. In our study, we selected two groups of voluntary CHF patients at the Xiangya 
Hospital, which were allowed to administrate Xinmailong or standard treatments, respectively. 
Another group of voluntary healthy individuals were recruited as the control group. The treatment 
effectiveness was measured by five symptomatic factors, i.e. angiotensin II (Ang_II), high sensitivity 
C-reactive protein (hs_CRP), Left Ventricular End Systolic Volume Index (LVESVI), left ventricular 
ejection fraction (LVEF) and pro-B-type natriuretic peptide (NT_proBNP), between the control 
group and the CHF patients at different stages of drug administration and in different treatment 
groups. The timeline for the full dose administration was set to 15 days and five measurements as 
indicated above were taken on every 0, 7th and 15th day of the drug administration respectively. In 
the conducted study, similar symptomatic measurements were observed on day 0 in both 
treatment groups, and slight improvements were observed on 7th day. It was observed that after 
a full course of drug administration for 15 days, both of the treatment groups achieved statistically 
significant improvements in all the five measures, but Xinmailong was found to be more (almost 
double) statistically significant as compared with the available drug treatments for chronic heart 
failure. 
Key words: Chronic heart failure, Traditional Chinese Medicine, Xinmailong. 
Introduction 
Heart failure, a common disorder, is due to im-
paired heart pumping ability, and the chronic heart 
failure (CHF) is usually induced by the damaged 
structure or function of the left ventricle [1, 2]. Alt-
hough CHF may occur at any age, it is most com-
monly observed in patients of 76 or older [3]. It has 
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been earlier reported that the ejection efficiency of left 
ventricle may be impaired by several diverse factors, 
which includes aging, diabetes, obesity, and acute 
myocardial infarction, etc [4, 5]. CHF's major symp-
toms include breath difficulty, ankle/leg swelling, 
and intolerance of even light exercises, etc [3], and it is 
usually treated with symptom relieving medications 
and implanted assist devices [6]. CHF is a common 
cardiovascular disease with more than 2% population 
coverage in the western countries [7, 8], but is rapidly 
becoming one of the most prevalent cardiovascular 
diseases in Asia, for example, case studies showed 
that CHF patients account for 0.9% of the Chinese 
population [9]. 
Even with more than 100 years of intensive 
studies, CHF still remains to have the worst progno-
ses and diagnosis treatment available as compared to 
the other chronic diseases, e.g. kidney failure and ar-
thritis, and most cancers [10]. It has been reported that 
approximately ~40% of the CHF patients die within 
the first year after diagnosis, and the five-year sur-
vival rate is only 25% for men and 38% for women, 
according to the Framingham study [11]. The high 
incidence of death rate and the non- availability of 
suitable drug treatments led to the particularly in-
creasing interest in developing early diagnosis and 
cardiovascular management techniques, so that suit-
able preventive measures can be designed for the 
identification and treatment of the CHF at an early 
stage [12], and to improve the life span and quality 
after its diagnosis [13]. 
Two types of chronic heart failure (CHF), viz. 
CHF with reduced (CHFrEF) or preserved (CHFpEF) 
ejection fractions, have been widely reported [14]. 
Available medication strategies for both types of CHF 
remains unsatisfactory as they largely cannot stop the 
disease progression and restore the quality of the pa-
tient's life [15]. It has been demonstrated that acute 
decompensated heart failure (ADHF) develops as the 
disease progresses, and has been found to be strongly 
correlated with the recurrent hospitalization and 
in-hospital mortality [16]. CHFrEF may be treated 
with sarcoplasmic reticulum calcium ATPase 2A ac-
tivators, to increase the sarcoplasmic reticulum (SR) 
uptake of calcium Ca2+, which is the central regulator 
of excitation-contraction coupling [17]. It is also es-
sential to maintain the Ca2+ releasing channel of the 
heart sarcoplasmic reticulum through the activated 
ryanodine receptor 2 and ryanodine receptor stabi-
lizers [18]. Novel therapies have been proposed for 
CHFrEF, including the growth promoting factor 
neuregulin-1 (NRG-1), which may facilitate the car-
diac chamber differentiation, and is already in the 
phase II clinical testing [19]. However, some major 
issues need to be addressed in CHF drug develop-
ment such as the organ specificity, since elevated ex-
pression of growth promoting factors in organs other 
than heart may also promote the tumor growth [20]. 
The renin-angiotensin aldosterone system (RAAS) is 
another ideal drug target, and multiple system inhib-
itors, e.g. angiotensin receptor blockers (ARBs), are 
clinically available [21]. CHFpEF accounts for the 
majority of CHF patients but no effective therapy is 
available as of now [22]. Two candidate therapeutic 
targets are the advanced glycation end products 
(AGEs) [23, 24] and the large cytoskeletal protein titin 
[25]. 
Since 2006, a number of Traditional Chinese 
Medicines (TCMs) were clinically tested on the CHF 
patients, including the warming yang strategy [26], 
nourishing yin strategy [27] and activating blood 
strategy [27, 28]. TCM is referred to both the medical 
practices developed during the last few thousand 
years in China and the medical materials from herbal 
and animal substances [29]. TCM practices based on 
physical therapy, acupuncture and dietary treatment 
represent a healthy complement to the western med-
ical practices, and already received legislations for 
professional practices in 43 states as of 2012. Califor-
nia established the first Acupuncture Board in 1975 to 
certify the professional acupuncturists [30]. Xin-
mailong was a bioactive composite extracted from 
periplaneta Americana, and showed reasonable protec-
tive effects against the cardiovascular injury. 
In our conducted research, we performed a sys-
tematic investigation of the potential effects of the 
Traditional Chinese Medicine (TCM), Xinmailong, on 
the chronic heart failure patients, as compared with 
the standard treatment using five measurements, i.e. 
Ang_II, hs_CRP, LVESVI, LVEF and NT_proBNP. A 
full course of 15 days was adopted and three time 
points (day 0, 7th and 15th) were chosen for measuring 
the five factors, and to do a time-series analysis. We 
observed that both treatments were found effective 
for CHF, in particular we observed that the Xin-
mailong showed almost double statistically signifi-
cant rate as compared with the available standard 
treatment. 
Methods 
Experimental protocol 
The present study was conducted to evaluate the 
potential therapeutic performance of the Chinese 
medicine, Xinmailong, on the chronic heart failure 
(CHF) patients, and to determine the optimal treat-
ment course. All the recruited CHF patients, including 
both in- and out-patients, visited the cardiovascular 
department of the Xiangya Hospital in the Central 
South University in China between October 2009 and 
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May 2011. To narrow down the investigation to the 
cardiovascular disorders, we excluded the patients 
with disorders such as liver or kidney diseases, dia-
betes, coagulation defects, endocrine disorders, ma-
lignant tumors, or desmosis. We also excluded the 
CHF patients with the history of habitual drinking or 
smoking, or receiving hormone replacement therapy. 
The control group was recruited from the healthy 
adults with office visits for regular physical examina-
tion in the above hospital during the same period of 
time. 
One data profile consists of a blood test and an 
echocardiography. The limosis blood samples were 
extracted from the cubital vein before 9:00 AM, with a 
pre-requisite that the voluntary participants were not 
allowed to have a meal at least 14 hours prior to the 
blood extraction procedure. Blood samples were col-
lected in an ice bathed test tube with 20 µl 0.3 mM 
EDTA, 20 µl 0.34 mM 8-oxychinolin, 10 µl 0.32 mM 
dimercaprol dimercaptopropanol. Then part of the 
blood sample was mixed evenly with the solution, 
before being centrifuged at 2000 g at 4ºC for 15 
minutes. The serum was kept for measuring the con-
centration of peptide hormone angiotensin II (Ang_II) 
by a radioimmunoassay. The serum level of the high 
sensitivity C-reactive protein (hs-CRP) was detected 
using the immune-fluorescence technique. The level 
of N terminal pro-B-type natriuretic peptide 
(NT-proBNP) was measured using the ReLTA Im-
muno-detection machine physically located in the 
clinical laboratory in the hospital. 
An ultrasonic cardiogram (UCG, also denoted as 
echocardiography) was taken for each voluntary par-
ticipant to calculate the left ventricular (LV) ejection 
fraction (LVEF) and Left Ventricular End Systolic 
Volume (LVESV). The body surface area (BSA) is 
calculated by the formula 0.0061×height 
(cm)+0.0128×weight (kg)-0.1529 [31, 32], and the Left 
Ventricular End Systolic Volume Index (LVESVI) is 
LVESV/BSA [33]. 
The five parameters, i.e. Ang_II, hs_CRP, 
LVESVI, LVEF and NT_proBNP, were investigated 
because they are the major factors to measure how 
well the heart pumps the blood and the blood carries 
the oxygen. 
Voluntary Participants 
In our conducted research, there were 104 
healthy participants in the control group, and all of 
them were diagnosed as normal (class I) based on the 
New York Heart Association (NYHA) Functional 
Classification system [34]. The control group was 
randomly split into the study group (69 participants, 
including 36 males and 33 females) and the test group 
(35 participants, including 19 males and 16 females). 
The two groups of normal participants were denoted 
as the normal study group (sNormal) and normal test 
group (tNormal), and they were combined into the 
group Normal, respectively.  
Based on the aforementioned criteria, the data of 
121 participants with NYHA class II-IV diagnosis 
were collected for further downstream analysis. The 
hypothesis obtained from one participant group 
(study group) will be independently validated on 
another group of participants (test group). Only hy-
pothesis holding for both the study and test groups is 
considered to be reasonable. So the 121 recruited par-
ticipants were randomly split into the study group (81 
participants, including 42 males and 39 females), and 
the test group (40 participants, including 25 males and 
15 females). We further divided randomly the heart 
failure study group into two groups to receive dif-
ferent treatments. Group sA has 40 patients (17, 20 
and 3 patients at NYHA class II, III and IV, respec-
tively), and received the standard treatment with dig-
italis preparation, diureticum, β-Blockers, sodium 
nitroprusside, enteric-coated aspirin. Group sB has 41 
patients (18, 20 and 2 patients at the NYHA class II, III, 
and IV, respectively), and received the intravenous 
injection of Xinmailong besides the standard treat-
ment, respectively. Each intravenous injection uses 
one dose of 4mL Xinmailong in 100mL 5% glucose. 
The test group was randomly split into two sub-
groups tA and tB, under standard and Xinmailong 
treatments. Both groups tA and tB consist of 5, 10 and 
5 patients for the NYHA class II, III and IV, respec-
tively. The group A consists of patients from sA and 
tA, and group B is combined from sB and tB.  
Each of the two groups of CHF patients took 
three measurements on day 0, 7th and 15th of the 
treatment. The datasets for the sub-group sA were 
denoted as sA0, sA7 and sA15, and those for tA were 
tA0, tA7 and tA15. Similar datasets were defined for 
sB and tB as sB0, sB7, sB15, tB0, tB7 and tB15, respec-
tively. All involved participants passed the skin test of 
Xinmailong. The present investigation was conducted 
in accordance to the ethical guidelines and was ap-
proved by the Ethics Committee of the Xiangya Hos-
pital, Central South University. All participants in-
volved in the conducted study signed the written in-
formed consent to voluntarily participate in this 
study. 
Statistical analysis 
All the statistical analysis was conducted using 
the program R version 2.15.2 (released on October 26, 
2012) [35] within the graphical user interface (GUI) of 
RStudio version 0.97.173 (released on November 10, 
2012) [36]. All the basal characteristics of the three 
groups of samples were summarized as Mean±Stdev, 
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where Mean is the averaged value across the group 
and Stdev is the observed standard deviation across 
the group. We further applied independent-sample 
t-test to compare the five measurements, i.e. Ang_II, 
hs-CRP, LVESVI, LVEF and NT-proBNP, of the 
groups of CHF patients (A∪B) and control individuals 
(Normal). The NYHA class differences of the two 
groups of CHF patients receiving different treatments 
were investigated using the Chi-square test. The age, 
blood pressure and the aforementioned five meas-
urements of the same two groups of CHF patients, i.e. 
A and B, were compared using the independ-
ent-sample t-test. All the following statistical proce-
dures were implemented on the five measured values, 
i.e. Ang_II, hs-CRP, LVESVI, LVEF and NT-proBNP. 
The differences between the two groups with differ-
ent treatments (A and B) were compared by the 
paired-sample t-test. We applied independent-sample 
t-test to compare the differences between the control 
group (Normal) and the two CHF patient groups (A 
and B), respectively. All the statistical correlations 
were considered significant if smaller than the P-value 
of 0.05. 
Results and Discussion 
Basal characteristics of the sample groups 
The basal characteristics of the measurements of 
all the participants are briefly discussed here. Firstly, 
we summarize the age of the studied groups Normal 
and A∪B, which are 57.90±5.49 and 58.56±5.96, re-
spectively. According to the null hypothesis that the 
distributions of ages in the two groups do not have 
differences, and the independent-sample t-test P-value 
to reject this null hypothesis is 0.3897, which is far 
from the threshold, 0.05. So we concluded that there is 
no obvious difference between the ages of the two 
groups. Table 1 shows slight to median differences in 
the diastolic (DBPs) and systolic blood pressures 
(SBPs) across the groups Normal and A∪B, with 
P-values 3.20e-2 and 6.36e-11, respectively. We specu-
late this as reasonable since most of the CHF patients 
tend to have heart disorders. The five measurements, 
i.e. Ang_II, hs-CRP, LVESVI, LVEF and NT-proBNP, 
are major factors to describe whether a heart works 
well, and are supposed to behave abnormally in the 
CHF patients. In our results, this demonstrated hy-
pothesis is well supported by the independent-sample 
t-test P-value, which is smaller than e-111 for all the 
five measurements, as shown in Table 1. 
In the present research, we divided the partici-
pants uniformly into two groups to receive different 
treatments for statistical evaluation. Except for the 
NYHA classes, all the other eight measurements of the 
two CHF patient groups A and B were compared with 
the independent-sample t-test, and the P-value was 
calculated in order to provide a basis for the rejection 
of the null hypothesis that there is no observed dif-
ference in the given measurement of groups A and B. 
The NYHA classes of the two groups of CHF patients 
were compared using the Pearson's chi squared test 
for the evaluation of the null hypothesis. We observed 
that the P-values of all the eight measurements be-
tween groups A and B are significantly higher than 
the threshold P-value of 0.05 (Table 2), which allowed 
us to conclude that there is no differences in the nine 
measurements between groups A and B. 
 
Table 1. Baseline characteristics of the study participants. 
SBP and DBP are the systolic and diastolic blood pressures, re-
spectively. Row Ang_II is the concentration of peptide hormone 
angiotensin II, measured in pg/ml. Row hs-CRP is the serum level of 
the high sensitivity C-reactive protein in mg/l. The level of amino 
terminal pro-B-type natriuretic peptide is given in the row 
NT_proBNP in pg/l. The LVEF and LVESVI are the left ventricular 
ejection fraction, and the left Ventricular End Systolic Volume 
Index, respectively. The P-values for all the measurements were 
calculated using the independent-sample t-test. The columns 
“Normal (n=104)” and “A∪B (n=121)” represent the data for the 
Normal group and the combined group of A and B. 
Variable Normal (n=104) A∪B (n=121) P-value 
Age (yr old) 57.90±5.49 58.56±5.96 3.90E-01 
SBP, mmHG 113.39±9.58 104.14±10.62 6.36E-11 
DBP, mmHG 73.29±6.22 75.47±8.88 3.20E-02 
Ang_II 31.81±5.06 94.15±6.12 3.07E-170 
hs_CRP 2.10±0.57 8.05±1.04 4.35E-118 
NT_proBNP 31.02±3.86 54.32±3.90 2.00E-141 
LVEF 59.38±3.07 35.77±3.10 1.36E-133 
LVESVI 104.11±9.29 4313.34±292.42 2.66E-112 
 
Table 2. Comparison between groups A and B before 
treatments. The variable NYHA is the class data of the NYHA 
classification of the CHF patients, and the class II, III and IV were 
converted to 2, 3 and 4, respectively, in order to calculate the 
averaged value and the standard deviation. The categorized NYHA 
classes were tested for the group difference using the Pearson's 
chi squared test [44]. The other eight measurements have the 
same meaning as in Table 1, and their P-values were calculated using 
the independent-sample t-test. 
Variable A (n=60) B (n=61) P-value 
NYHA 2.77±0.67 2.75±0.67 9.93E-01 
Age (yr old) 58.37±5.88 58.75±6.07 7.22E-01 
SBP (mmHG) 104.72±10.93 103.57±10.36 5.56E-01 
DBP (mmHG) 75.68±9.05 75.26±8.77 7.95E-01 
Ang_II (pg/ml) 94.25±6.02 94.05±6.26 8.58E-01 
hs_CRP (mg/l) 8.07±1.04 8.02±1.04 7.79E-01 
LVESVI 54.43±4.05 54.21±3.78 7.58E-01 
LVEF 35.73±3.00 35.80±3.21 9.02E-01 
NT_proBNP (pg/l) 4312.40±292.66 4314.26±294.60 9.72E-01 
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Both the standard and Xinmailong treatments 
are effective 
In the comparative assessment of the Xinmailong 
and the currently available standard treatment, we 
further observed that improvement in all the five 
measurements of the CHF patient group A after the 
standard treatments, as shown in Table 3. Angiotensin 
II (Ang_II) is a peptide hormone that constricts arter-
ies and veins in the heart and therefore increases the 
blood pressure [37]. It has been observed that the ac-
tivity of the Angiotensin II (Ang_II) in serum level is 
usually increased in the CHF and hypertension pa-
tients [38]. We observed that both the datasets sA and 
tA have decreased serum levels of Ang_II after seven 
days of the standard treatment, which is well sup-
ported by strong P-values 2.67e-12 and 5.39e-6 to reject 
the null hypothesis that the Ang_II observed level was 
the same after the treatment. We clearly observed a 
further decrease in the Ang_II levels after one more 
week of treatment, and the much higher decreases are 
supported by the P-values 1.73e-33 and 5.01e-12, re-
spectively. High sensitivity C-reactive protein 
(hs_CRP) is a protein whose serum level is positively 
correlated with the inflammation in the body, and 
amino terminal pro-B-type natriuretic peptide 
(NT_proBNP) is the N-termini of the brain natriuretic 
peptide whose serum level is positively associated 
with the CHF severeness [39]. The serum levels of 
both molecules are used as markers to describe how 
severe the cardiac risk is [39]. The continuous de-
creases in the two molecular levels after the standard 
treatment in days 7 and 15 suggest that the treatment 
works reasonably well on CHF, as shown in Table 3. 
The left ventricular (LV) ejection fraction (LVEF) is the 
volumetric percentage of blood pumped out of the left 
ventricular in one heart beat, and the reduced LVEF is 
associated with the poorer CHF prognoses [40, 41]. 
And the Left Ventricular End Systolic Volume Index 
(LVESVI) is calculated by the ratio between the left 
ventricular (LV) end-systolic volume and the body 
surface area, which is positively associated with the 
CHF prognoses [42]. The effectiveness of the standard 
treatment is further supported by the significantly 
increased LVEF and decreased LVESVI. 
 
Table 3. Differences of the four CHF patient groups, sA, tA, sB and tB, at day 0 compared with days 7 and 15, respec-
tively. Column Variable gives the names of the five measurements. The data of the five measurements for the four patient groups are 
given in the second, third and fifth columns, respectively. The fourth column is the list of P-values between days 0 and 7 for the four patient 
groups, and the sixth column gives the P-values calculated between days 0 and 15. The P-values in this table were calculated using the 
paired-sample t-test [45]. 
Variable sA0 sA7 sA0 vs sA7 sA15 sA0 vs sA15 
Ang_II (pg/ml) 94.83±6.13 93.40±6.12 2.67E-12 70.62±5.59 1.73E-33 
hs_CRP (mg/l) 8.11±1.04 7.91±1.03 1.42E-03 5.77±0.94 1.33E-34 
LVESVI 54.27±4.09 53.25±3.81 6.95E-10 47.08±3.80 3.08E-30 
LVEF 36.85±2.78 37.62±2.68 2.32E-04 41.62±2.38 4.43E-29 
NT_proBNP (pg/l) 4318.57±298.86 4103.65±419.12 5.96E-06 3111.80±409.03 1.24E-31 
Variable tA0 tA7 tA0 vs tA7 tA15 tA0 vs tA15 
Ang_II (pg/ml) 93.10±5.75 92.00±5.80 5.39E-06 71.10±8.37 5.01E-12 
hs_CRP (mg/l) 8.00±1.07 7.82±1.06 1.47E-04 5.54±0.98 4.08E-19 
LVESVI 54.75±4.05 53.60±3.99 4.51E-06 47.40±3.97 8.63E-17 
LVEF 33.50±2.04 34.30±2.41 5.80E-05 38.60±2.82 2.17E-16 
NT_proBNP (pg/l) 4300.05±287.04 3211.80±295.34 1.92E-20 2149.60±259.82 3.27E-15 
Variable sB0 sB7 sB0 vs sB7 sB15 sB0 vs sB15 
Ang_II (pg/ml) 94.56±6.39 93.34±6.48 5.50E-11 47.51±6.98 9.63E-38 
hs_CRP (mg/l) 8.07±1.04 7.66±1.04 2.16E-11 3.11±0.63 1.15E-33 
LVESVI 53.95±3.85 52.78±3.81 6.04E-14 40.56±3.27 8.10E-35 
LVEF 36.90±3.09 37.54±3.09 8.64E-07 46.37±2.46 3.74E-25 
NT_proBNP (pg/l) 4321.17±301.67 3935.17±401.83 8.22E-17 2065.41±371.46 7.89E-37 
Variable tB0 tB7 tB0 vs tB7 tB15 tB0 vs tB15 
Ang_II (pg/ml) 93.00±6.01 91.90±5.97 1.99E-04 48.00±8.57 6.23E-16 
hs_CRP (mg/l) 7.93±1.06 7.77±1.00 4.88E-04 3.26±0.89 1.87E-11 
LVESVI 54.75±3.65 53.25±3.39 3.92E-07 40.85±3.77 9.82E-18 
LVEF 33.55±2.14 34.45±2.46 2.98E-04 42.55±2.87 2.97E-13 
NT_proBNP (pg/l) 4300.10±286.65 3210.80±294.84 1.70E-20 1390.60±238.24 9.96E-20 
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The Xinmailong treatment seems to facilitate 
greater improvements on the CHF symptoms. Xin-
mailong is a composite extract made from periplaneta 
americana, and its effective constituent was shown to 
have significant protection of cardiovascular cells 
from the hypoxia-ischemic myocardial injury [43]. Its 
effective constituents still remain unknown. Firstly, 
Table 3 suggests that the Xinmailong treatment also 
effectively soothes the CHF symptoms, e.g. blood 
pressure (Ang_II), inflammation levels (hs_CRP), and 
heart physiological functions (LVEF and LVESVI). 
Secondly, the Xinmailong treatment induces the 
slightly greater decreases for all the measurements 
except for LVEF than the standard treatment by 
comparing sA7 vs sB7, and tA7 vs tB7. After 15 days, 
the Xinmailong treatment induces much better im-
provements in the four measurements than the 
standard treatment by comparing sA15 vs sB15, and 
tA15 vs tB15, and the P-values also support the signif-
icances. The Xinmailong treatment induces slightly 
worse improvement in the measurement LVEF com-
pared with the standard treatment, but LVEF is 
known to be low in the CHF prediction sensitivity 
[42]. LVESVI was demonstrated to be a better CHF 
prognoses marker, with accurate predictions even in 
CHF patients with normal LVEF values [42].  
A full course of 15 days is necessary for both 
treatments 
We further investigated the treatment effective-
ness by comparing the five measurements in the da-
taset Normal with those in the two CHF patient da-
tasets A and B, respectively. The reduced difference of 
a measurement of a CHF patient dataset compared 
with the normal dataset is considered as an im-
provement for this measurement, and the P-value 
calculated by the independent-sample t-test shows 
how significant the two datasets are different to each 
other. For the standard treatment, we firstly com-
pared the two study participant groups, sNormal and 
sA. On day 0 of the treatment, sA0 is significantly dif-
ferent from sNormal in all the five measurements, with 
P-values 7.31e-61, 2.04e-36, 1.66e-44, 8.00e-54 and 
9.77e-47 for Ang_II, hs_CRP, LVESVI, LVEF and 
NT_proBNP, respectively. After 7 days of the stand-
ard treatment, the CHF patients in the dataset sA7 
have slightly improvements in the five measurements, 
i.e. increase for LVEF and decrease for the other four. 
But the P-values of the two calculations “sA0 vs sN” 
and “sA7 vs sN” do not support that LVESVI and 
LVEF were significantly improved.  
We also calculated the P-values of LVESVI and 
LVEF between the two datasets sA0 and sA7, and 
they got 0.25 and 0.21 in P-values using the inde-
pendent-sample t-test, respectively. The data suggests 
that although Table 3 shows the significant im-
provements of LVESVI and LVEF for each CHF pa-
tient in column “sA0 vs sA7” with the paired-sample 
t-test P-values 6.95e-10 and 2.32e-4 (Table 3), but the 
two measurements after 7 days of treatment are still 
within the range of the CHF patients without treat-
ment. All the five measurements show further im-
provements after day 15th of the treatment, with sig-
nificantly increased P-values. The test datasets tA0, 
tA7 and tA15 show similar improvements in all the 
five measurements with prolonged treatment period, 
as shown in Table 4. Although Table 3 suggests that 
the five measurements of individual CHF patients 
were significantly improved for the comparisons “tA0 
vs tA7” and “tA0 vs tA15”, the group-wise compari-
sons between the dataset tA0 and tA7 only support 
the improvement significance of NT_proBNP with 
P-value 2.74e-14 (<0.05). But all the five measurements 
were significantly improved after 15 days of the 
standard treatment, with the P-values < 0.05 calculated 
by using both paired-sample t-test (Table 3) and in-
dependent-sample t-test (Table 4). 
The Xinmailong treatment also showed greater 
improvements in the five measurements, which might 
be facilitated with longer treatment period, and we 
further observed that the five measurements were 
only slightly improved during the middle (day 7th) of 
the Xinmailong treatment, as show in Table 3 and 
Table 4. 
Xinmailong works better than the standard 
treatment 
Initially, we observed that both Xinmailong and 
standard treatments showed similar improvements 
on day 7, but Xinmailong showed significantly better 
enhancement than the standard treatment after a full 
course of 15 days. Both Table 3 and Table 4 show the 
differences of the improvements on days 7 and 15 for 
the two treatments, and we investigated the statistical 
significance of the differences. Figure 1 (a) shows how 
Ang_II was improved during the course of 15 days for 
the two treatments. As similarly in Table 3 and Table 
4, the Xinmailong treatment doesn't show big differ-
ence on day 7 compared with the standard treatment 
in the study datasets sA7 and sB7 with P-value 9.67e-1 
in Table 5. Both treatments showed significant im-
provements of the serum Ang_II levels after 15 days 
of treatments, and Xinmailong showed greater de-
crease of Ang_II in the serum than the standard 
treatment with P-value 7.97e-27 ("sA15 vs sB15" in 
Table 5). The same differences were also observed in 
the test datasets tA7, tB7, tA15 and tB15 in Table 5. 
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The other four measurements also supported this ob-
servation. 
Figure 1 illustrates that Xinmailong significantly 
restored the five measurements toward the healthy 
status after 15 days of treatment, and almost doubled 
the improvements compared with the standard 
treatment. We tested the hypothesis on the study da-
tasets that the Xinmailong's improvement on Ang_II, 
i.e. Ang_II(sB15)-Ang_II(sB0), doubles the standard 
treatment's improvement, i.e. 2×[Ang_II(sA15)-Ang_ 
II(sA0)]. The P-value 3.31e-1 in Table 5 cannot reject 
the hypothesis. And the investigation on the test da-
tasets also supports that Xinmailong's improvement 
on Ang_II doubles that of the standard treatment, 
with rejecting P-value 7.71e-1. The other four meas-
urements support this hypothesis on both study and 
test datasets, except for the test datasets of LVEF and 
NT_proBNP. The test dataset of LVEF gives a mar-
ginal P-value 4.04e-2<0.05 to reject the hypothesis, and 
that of NT_proBNP rejects the hypothesis convinc-
ingly with P-value 1.45e-13, as shown in Table 5. We 
may judge from Figure 1 (d) and (e) that Xinmailong 
facilitates greater but not doubled improvements on 
LVEF and NT_proBNP on both study and test da-
tasets than the standard treatment. A further investi-
gation for the underlining mechanism of Xinmailong 
treatment and a better treatment protocol may be 
conducted. 
 
Table 4. Comparison of the CHF patient groups on the days 0, 7 and 15 during the treatments. Column Variable gives the 
names of the five measurements. For each of the four datasets, sA, tA, sB and tB, the second column (sN and tN) gives the averaged value 
and the standard deviation of the study and test Normal datasets. The 3th and 4th columns give the measurements of the CHF patients on 
day 0 of the treatment and their P-values compared with the Normal datasets. The 5th, 6th, 7th and 8th columns are defined in a similar way. 
Variable sN sA0 sA0 vs sN sA7 sA7 vs sN sA15 sA15 vs sN 
Ang_II (pg/ml) 31.57±5.38 94.83±6.13 7.31E-61 93.40±6.12 2.82E-60 70.62±5.59 1.65E-50 
hs_CRP (mg/l) 2.30±0.56 8.11±1.04 2.04E-36 7.91±1.03 6.87E-36 5.77±0.94 2.52E-28 
LVESVI 30.65±4.00 54.27±4.09 1.66E-44 53.25±3.81 4.24E-46 47.08±3.80 6.70E-36 
LVEF 59.68±2.43 36.85±2.78 8.00E-54 37.62±2.68 1.06E-54 41.62±2.38 3.95E-54 
NT_proBNP (pg/l) 103.90±9.27 4318.57±298.86 9.77E-47 4103.65±419.12 3.79E-40 3111.80±409.03 8.60E-36 
Variable tN tA0 tA0 vs tN tA7 tA7 vs tN tA15 tA15 vs tN 
Ang_II (pg/ml) 32.29±4.38 93.10±5.75 4.68E-29 92.00±5.80 1.47E-28 71.10±8.37 1.52E-16 
hs_CRP (mg/l) 1.70±0.33 8.00±1.07 2.24E-17 7.82±1.06 3.17E-17 5.54±0.98 6.78E-14 
LVESVI 31.74±3.53 54.75±4.05 1.06E-21 53.60±3.99 2.87E-21 47.40±3.97 9.68E-17 
LVEF 58.77±4.02 33.50±2.04 2.36E-35 34.30±2.41 1.50E-33 38.60±2.82 2.29E-27 
NT_proBNP (pg/l) 104.51±9.45 4300.05±287.04 7.51E-24 3211.80±295.34 3.77E-21 2149.60±259.82 8.78E-19 
Variable sN sB0 sB0 vs sN sB7 sB7 vs sN sB15 sB15 vs sN 
Ang_II (pg/ml) 31.57±5.38 94.56±6.39 4.35E-60 93.34±6.48 1.01E-58 47.51±6.98 1.88E-19 
hs_CRP (mg/l) 2.30±0.56 8.07±1.04 2.94E-37 7.66±1.04 1.06E-35 3.11±0.63 1.83E-09 
LVESVI 30.65±4.00 53.95±3.85 8.12E-48 52.78±3.81 1.63E-46 40.56±3.27 2.69E-25 
LVEF 59.68±2.43 36.90±3.09 6.26E-50 37.54±3.09 4.45E-49 46.37±2.46 1.01E-43 
NT_proBNP (pg/l) 103.90±9.27 4321.17±301.67 9.64E-48 3935.17±401.83 4.02E-41 2065.41±371.46 4.70E-31 
Variable tN tB0 tB0 vs tN tB7 tB7 vs tN tB15 tB15 vs tN 
Ang_II (pg/ml) 32.29±4.38 93.00±6.01 6.62E-28 91.90±5.97 8.16E-28 48.00±8.57 5.60E-08 
hs_CRP (mg/l) 1.70±0.33 7.93±1.06 2.18E-17 7.77±1.00 9.12E-18 3.26±0.89 1.55E-07 
LVESVI 31.74±3.53 54.75±3.65 6.06E-24 53.25±3.39 1.38E-24 40.85±3.77 1.14E-10 
LVEF 58.77±4.02 33.55±2.14 3.95E-35 34.45±2.46 3.52E-33 42.55±2.87 7.61E-23 
NT_proBNP (pg/l) 104.51±9.45 4300.10±286.65 7.31E-24 3210.80±294.84 3.68E-21 1390.60±238.24 9.79E-16 
 
Table 5. Comparison of P-values calculated between the five measurements of the four datasets, i.e. "sA7 vs sB7", "tA7 vs 
tB7", "sA15 vs sB15" and "tA15 vs tB15", respectively. The last two columns compared the improvements of the five measurements on day 
15 for the study and test datasets of the two treatments, respectively. The P-value was calculated between the two datasets with the 
independent-sample t-test [45]. 
Variable sA7 vs sB7 tA7vs tB7 sA15 vs sB15 tA15 vs tB15 2*(sA15-sA0) vs (sB15-sB0) 2*(tA15-tA0) vs (tB15-tB0) 
Ang_II (pg/ml) 9.67E-01 9.57E-01 7.97E-27 1.78E-10 3.31E-01 7.71E-01 
hs_CRP (mg/l) 2.87E-01 8.85E-01 3.39E-23 3.42E-09 1.39E-01 5.02E-01 
LVESVI 5.81E-01 7.67E-01 3.28E-12 4.44E-06 6.55E-02 2.15E-01 
LVEF 8.91E-01 8.47E-01 2.22E-13 8.76E-05 8.80E-01 4.04E-02 
NT_proBNP (pg/l) 6.87E-02 9.92E-01 1.82E-19 1.04E-11 8.26E-02 1.45E-13 
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Figure 1. Box plots of the five measurements of the four 
datasets, i.e. sA, sB, tA and tB, of (a) Ang_II, (b) hs_CRP, (c) 
LVESVI, (d) LVEF and (e) NT_proBNP. Each sub-figure groups the 
study and test groups together, respectively. A direct comparison 
was conducted between sA0 vs sB0, sA7 vs sB7, and sA15 vs sB15. 
So each of such pairs was plotted together. Similar setting was 
used for tA0 vs tB0, tA7 vs tB7, and tA15 vs tB15. The data sug-
gested that the treatment B is much better than A, and almost 
doubled the treatment effects after a full course of 15-day 
treatments. 
 
 
 
 
 
Conclusion 
In our study, we conclude that Xinmailong rep-
resents a promising Traditional Chinese Medicine for 
the cardiovascular diseases, and is currently adopted 
as an optional treatment for the CHF patients in the 
Xiangya Hospital and a number of other large hospi-
tals in China. The data presented in this study sug-
gests that Xinmailong may effectively restore the 
multiple cardiovascular measurements to the normal 
levels, and achieves the doubled improvements in 
these measurements compared with the available 
standard treatment. Subsequent studies of Xin-
mailong on other cardiovascular diseases are being 
planned, and the effective constituents of Xinmailong 
are being screened. 
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